Literature DB >> 7448342

Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.

T Taylor, L F Chasseaud, E Doyle, A Darragh, D A O'Kelly, D Fitzgerald.   

Abstract

Plasma concentrations of isosorbide dinitrate have been measured after intravenous infusion of drug at a rate of 5.0 mg h-1 for 150 min and after single equal oral doses of 12.5 mg of drug in solution to two normal human subjects. During the infusion, uneven plateau concentrations were approached after 30 min. The calculated average steady-state plasma levels were 258 ng ml-1 and 514 ng ml-1 in the two subjects respectively. The half-life of elimination of isosorbide dinitrate after termination of the infusion was 9--10 min. After oral doses, peak plasma levels of 26.6 ng ml-1 and 12.7 ng ml-1 occurred at 10 min and 20 min in the two subjects respectively. The terminal half-life of drug after the oral doses was much longer than the elimination half-life (about 10 min), and was associated with the absorption phase. Fairly good agreement was obtained between the observed concentrations and those predicted by a one-compartment open model. The systemic availability of isosorbide dinitrate after the oral doses was up to only 3 per cent of the equal doses infused, indicating that presystemic elimination processes accounted for very large proportions of the oral doses. The systemic clearances of drug after infusion of 0.32 l min-1 and 0.16 l min-1 were unexpectedly low for a drug of reported high liver extraction ratio.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7448342     DOI: 10.1002/bdd.2510010310

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  11 in total

1.  Intra-individual comparison of the action of equal doses of isosorbide-5-endomononitrate, slow-release isosorbide dinitrate and placebo in patients with coronary heart disease.

Authors:  G Müller; W Häcker; B Schneider
Journal:  Klin Wochenschr       Date:  1983-04-15

2.  Prolonged plasma half-life after oral isosorbide dinitrate in patients with angina pectoris.

Authors:  H L Fung; J O Parker
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

3.  Availability of isosorbide dinitrate, diazepam and chlormethiazole, from i.v. delivery systems.

Authors:  P A Cossum; M S Roberts
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

4.  Endoscopic variceal pressure measurements: response to isosorbide dinitrate.

Authors:  J Dawson; P Gertsch; F Mosimann; R West; E Elias
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

5.  Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.

Authors:  Y Santoni; A Iliadis; J P Cano; R Luccioni; Y Frances
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

Review 6.  Clinical pharmacokinetics of organic nitrates.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

7.  Fate of isosorbide dinitrate and mononitrates in patients with renal failure.

Authors:  M G Bogaert; M T Rosseel; J Boelaert; R Daneels
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Isosorbide-5-mononitrate in the treatment of acute left ventricular failure following acute myocardial infarction.

Authors:  M D Gammage; R G Murray; W A Littler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Glyceryl trinitrate (nitroglycerin) ointment and isosorbide dinitrate: a review of their pharmacological properties and therapeutic use.

Authors:  U Elkayam; W S Aronow
Journal:  Drugs       Date:  1982-03       Impact factor: 9.546

10.  Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate.

Authors:  U Abshagen; G Betzien; R Endele; B Kaufmann
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.